Tag: intellia

November 13, 2018

CRISPR Trials to Watch in 2018

CRISPR Cas-9 gene editing is finally in clinical studies. Here's an overview of CRISPR genetics testing trials currently in progress.
March 14, 2018

Intellia Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results

Intellia Therapeutics (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR technology, announced financial results and...
March 8, 2018

4 Gene Editing Technologies Explained

We look at four types of gene editing currently in clinical trials, as well as the pros and cons of...
February 27, 2018

Intellia Therapeutics Announces Publication in Cell Reports of Preclinical Data Demonstrating Effective CRISPR/Cas9 Genome Editing

Intellia Therapeutics (NASDAQ:NTLA), a leading genome editing company developing curative therapeutics using CRISPR/Cas9 technology, announced that Cell Reports will publish at noon...
October 5, 2017

4 Gene Therapy Stocks to Watch in 2017

At the halfway mark of 2017, here's a look at how these four gene therapy companies are performing so far...
August 1, 2017

Intellia Therapeutics Posts Q2 Financial Report

Intellia Therapeutics released its financial results for the second quarter of 2017.
March 9, 2017

Genetics Facts for Investors

Punnett squares and phenotypes, chromatids and codominance: genetics, and all of its associated terms, isn’t the easiest field to understand....